Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting malaria with specific CDK inhibitors.

Jeanne A Geyer1, Sean T Prigge, Norman C Waters

  • 1Diagnostic Systems Division, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Ft. Detrick, MD 20910, USA. Jeanne.Geyer@det.amedd.army.mil

Biochimica Et Biophysica Acta
|September 28, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inheritance of four-membrane-bound structures in the "apicoplast-minus" <i>Plasmodium falciparum</i>.

mSphere·2026
Same author

Genetic analysis of pyrimidine biosynthetic enzymes in Plasmodium falciparum.

PLoS pathogens·2026
Same author

Acyl Carrier Protein is Essential for Apicoplast Biogenesis in Malaria Parasites Independent of Fatty Acid Synthesis.

bioRxiv : the preprint server for biology·2026
Same author

Genetic relatedness of Cambodian <i>Plasmodium falciparum</i> isolates is driven by geography and occupation.

medRxiv : the preprint server for health sciences·2026
Same author

Genetic analysis of pyrimidine biosynthetic enzymes in <i>Plasmodium falciparum</i>.

bioRxiv : the preprint server for biology·2025
Same author

An essential adaptor for apicoplast fission and inheritance in malaria parasites.

Nature communications·2025

Researchers identified novel inhibitors for Plasmodium falciparum kinase (Pfmrk), a key target in malaria drug discovery. These selective inhibitors show promise for treating malaria by targeting parasite cell growth.

Area of Science:

  • Medicinal Chemistry
  • Parasitology
  • Drug Discovery

Background:

  • Cyclin-dependent kinases (CDKs) are crucial for cell regulation and are targeted for various diseases.
  • CDKs are essential for the growth and differentiation of the malaria parasite Plasmodium falciparum.
  • Pfmrk, a Plasmodium falciparum CDK and homolog of human CDK7, is a promising target for antimalarial drug development.

Purpose of the Study:

  • To identify and refine chemical inhibitors targeting the Plasmodium falciparum CDK, Pfmrk.
  • To develop and validate a pharmacophore model for Pfmrk inhibitors.
  • To understand the molecular basis of Pfmrk inhibitor specificity through molecular modeling.

Main Methods:

  • Employed experimental and virtual screening to identify Pfmrk inhibitors.

Related Experiment Videos

  • Developed and validated a pharmacophore model based on known Pfmrk inhibitors.
  • Utilized molecular modeling and docking to analyze the Pfmrk active site and inhibitor interactions.

    • Main Results:

    • Identified diverse chemotypes (purines, quinolinones, oxindoles, chalcones) with sub-micromolar IC50 values against Pfmrk.
    • Developed a validated pharmacophore model leading to the discovery of additional potent Pfmrk inhibitors.
    • Molecular modeling revealed key amino acid differences in the Pfmrk ATP binding pocket compared to human CDKs, explaining inhibitor selectivity.

    Conclusions:

    • PfMRK is a viable drug target for antimalarial agents.
    • The identified inhibitors and pharmacophore model provide a strong foundation for developing new antimalarial drugs.
    • Distinctive active site features of Pfmrk offer opportunities for highly selective antimalarial drug design.